How Much Do Antiretroviral Drugs Penetrate into the Central Nervous System?

Overview

Journal J Med Life

Specialty General Medicine

Date 2012 Apr 20

PMID 22514580

Citations 56

Authors

L Ene

D Duiculescu

S M Ruta

Affiliations

Soon will be listed here.

Abstract

The central nervous system can act as a compartment in which HIV can replicate independently from plasma, and also as a sanctuary in which, under suboptimal drug pressure, HIV antiretroviral genetic variants can occur. Continuous replication of HIV in brain can contribute to neurocognitive impairment. Therefore, reaching adequate concentrations of antiretrovirals in the central nervous system might be essential in providing neuroprotection and improving neurocognition. Antiretrovirals have a restricted entry into the brain, due to several factors: the unique structure of the blood-brain barrier, and the existence of efficient efflux mechanisms. However, there is a high variability of antiretrovirals in reaching therapeutic drug concentrations in cerebrospinal fluid, that depend on the characteristics of the antiretrovirals (molecular weight, lipophilicity, protein binding) and on their capacity to be substrate for efflux transporters. The review aims to discuss the main mechanisms that interfere with antiretroviral penetration into central nervous system, and to summarize the current data concerning the penetrability of different antiretrovirals into the cerebrospinal fluid.

Citing Articles

HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives.

Kelly S, Nightingale S, Gupta R, Collier D Trop Med Infect Dis. 2025; 10(2).

PMID: 39998049 PMC: 11860496. DOI: 10.3390/tropicalmed10020045.

The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection.

Murzin A, Elfimov K, Gashnikova N Pathogens. 2025; 14(1).

PMID: 39860976 PMC: 11768375. DOI: 10.3390/pathogens14010015.

Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development.

LaNoce E, Zhang D, Garcia-Epelboim A, Su Y, Sun Y, Alepa G Front Mol Neurosci. 2024; 17:1459877.

PMID: 39569018 PMC: 11576471. DOI: 10.3389/fnmol.2024.1459877.

Nucleoside and non-nucleoside reverse transcriptase inhibitor drugs (NRTIs and NNRTIs) are capable of binding Chandipura virus polymerase protein (L) and inhibit virus replication.

Mandal D, Pandey D, Sarkar D, Kumar M Virusdisease. 2024; 35(3):420-427.

PMID: 39464733 PMC: 11502645. DOI: 10.1007/s13337-024-00883-w.

Examining the effects of the HIV-1 protein Tat and morphine on antiretroviral accumulation and distribution within the brain.

Jones A, Rademeyer K, Rosen E, Contaifer S, Wijesinghe D, Hauser K Clin Transl Sci. 2024; 17(10):e70035.

PMID: 39382215 PMC: 11462598. DOI: 10.1111/cts.70035.

References

Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli W . Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2006; 35(3):340-4. DOI: 10.1124/dmd.106.012765. View

Jong A, Huang S . Blood-brain barrier drug discovery for central nervous system infections. Curr Drug Targets Infect Disord. 2005; 5(1):65-72. DOI: 10.2174/1568005053174672. View

Shaik N, Pan G, Elmquist W . Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci. 2008; 97(12):5421-33. PMC: 5096432. DOI: 10.1002/jps.21372. View

Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S . Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos. 2008; 36(8):1476-84. PMC: 5091086. DOI: 10.1124/dmd.108.020974. View

van Praag R, van Weert E, van Heeswijk R, Zhou X, Sommadossi J, Jurriaans S . Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother. 2002; 46(3):896-9. PMC: 127501. DOI: 10.1128/AAC.46.3.896-899.2002. View

van Lelyveld S, Nijhuis M, Baatz F, Wilting I, van den Bergh W, Kurowski M . Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis. 2010; 50(3):387-90. DOI: 10.1086/649874. View

Varatharajan L, Thomas S . The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009; 82(2):A99-109. PMC: 2678986. DOI: 10.1016/j.antiviral.2008.12.013. View

Smit T, Wang B, Ng T, Osborne R, Brew B, Saksena N . Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without AIDS dementia complex (ADC): evidence for neurotropic HIV variants. Virology. 2001; 279(2):509-26. DOI: 10.1006/viro.2000.0681. View

Capparelli E, Letendre S, Ellis R, Patel P, Holland D, McCutchan J . Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother. 2005; 49(6):2504-6. PMC: 1140502. DOI: 10.1128/AAC.49.6.2504-2506.2005. View

10.

Baldwin S, Beal P, Yao S, King A, Cass C, Young J . The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2003; 447(5):735-43. DOI: 10.1007/s00424-003-1103-2. View

11.

Burger D, Kraayeveld C, Meenhorst P, Mulder J, Hoetelmans R, Koks C . Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci. 1995; 17(6):218-21. DOI: 10.1007/BF01870615. View

12.

Yilmaz A, Izadkhashti A, Price R, Mallon P, De Meulder M, Timmerman P . Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses. 2009; 25(4):457-61. PMC: 2853865. DOI: 10.1089/aid.2008.0216. View

13.

Antinori A, Perno C, Giancola M, Forbici F, Ippolito G, Hoetelmans R . Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005; 41(12):1787-93. DOI: 10.1086/498310. View

14.

Tashima K, Caliendo A, Ahmad M, Gormley J, Fiske W, Brennan J . Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999; 180(3):862-4. DOI: 10.1086/314945. View

15.

Simpson D . Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clin Infect Dis. 1999; 29(1):19-34. DOI: 10.1086/520150. View

16.

Smit T, Brew B, Tourtellotte W, Morgello S, Gelman B, Saksena N . Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004; 78(18):10133-48. PMC: 515019. DOI: 10.1128/JVI.78.18.10133-10148.2004. View

17.

Sinclair E, Ronquillo R, Lollo N, Deeks S, Hunt P, Yiannoutsos C . Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008; 47(5):544-52. PMC: 3480328. DOI: 10.1097/QAI.0b013e318162754f. View

18.

Burger D, Kraaijeveld C, Meenhorst P, Mulder J, Koks C, Bult A . Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS. 1993; 7(12):1581-7. DOI: 10.1097/00002030-199312000-00006. View

19.

Heaton R, Marcotte T, Rivera Mindt M, Sadek J, Moore D, Bentley H . The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004; 10(3):317-31. DOI: 10.1017/S1355617704102130. View

20.

Gibbs J, Jayabalan P, Thomas S . Mechanisms by which 2',3'-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy. J Neurochem. 2003; 84(4):725-34. DOI: 10.1046/j.1471-4159.2003.01560.x. View